What is the recommended management for each stage of type 1 diabetes (stage 1: multiple islet autoantibodies with normal glucose and no symptoms; stage 2: autoantibodies with abnormal glucose but asymptomatic; stage 3: symptomatic type 1 diabetes)?

Management of Type 1 Diabetes by Stage

For Stage 1 and Stage 2 type 1 diabetes, refer patients to specialized centers for monitoring and consideration of approved disease-modifying therapy or clinical trial enrollment; Stage 3 requires immediate insulin therapy and standard diabetes management. 1

Stage 1: Multiple Islet Autoantibodies with Normoglycemia

Monitoring Protocol:

• Biannual assessments (every 6 months) for children: random plasma glucose and HbA1c 2, 3
• Annual assessments for adolescents and adults: same parameters 2
• Specialist referral is essential when multiple islet autoantibodies are confirmed 1

Key Actions:

• Confirm autoantibody positivity with a second sample before proceeding 3
• Educate patients and families about symptoms of hyperglycemia and diabetic ketoacidosis (DKA) 3
• Consider genetic risk assessment and autoantibody titers to refine individual risk stratification 1
• Evaluate eligibility for clinical trials aimed at preventing progression 1

Risk Context: At Stage 1, there is a 44% risk of progressing to symptomatic diabetes within 5 years, though this varies considerably based on autoantibody number, titer, specificity, age of seroconversion, and genetic factors 1, 4.

Stage 2: Autoantibodies with Dysglycemia (Asymptomatic)

Monitoring Protocol:

• 3-monthly clinic visits with more intensive surveillance 2, 3
• Home glucose monitoring in addition to clinic assessments 2
• Consider continuous glucose monitoring (CGM) to detect early metabolic deterioration 5, 2
• Repeat oral glucose tolerance testing (OGTT) may be valuable for tracking progression 2

Key Actions:

• Immediate specialist referral for approved therapy or clinical trial enrollment 1
• Intensified education about DKA symptoms and when to seek emergency care 3
• Psychosocial support should be integrated into care 3, 6
• Close partnership between endocrinologists and primary care providers 3

Risk Context: Stage 2 carries a 60% risk of progression to clinical diabetes within 2 years and 75% within 5 years 1, 4. This is the critical window for disease-modifying interventions.

Common Pitfall: Do not delay specialist referral in Stage 2—this is when approved therapies (such as teplizumab) can delay progression to Stage 3 and when intervention has the greatest potential impact on preserving beta-cell function.

Stage 3: Symptomatic Type 1 Diabetes

Immediate Management:

• Initiate insulin therapy immediately upon diagnosis 1
• Assess for and treat DKA if present—children and adolescents frequently present with DKA as the first manifestation 1
• Measure C-peptide to document residual beta-cell function (useful for differential diagnosis and tracking therapeutic responses) 7

Standard Diabetes Care:

• Comprehensive diabetes education and self-management training
• Blood glucose monitoring or CGM implementation
• Nutritional counseling and insulin dose adjustment training
• Screen for and manage acute complications (hypoglycemia, hyperglycemia, DKA)
• Begin surveillance for chronic complications per standard guidelines

Important Considerations:

• Beta-cell destruction rate varies widely—rapid in children, potentially slower in adults 1
• Adults may retain sufficient beta-cell function to avoid DKA for years but remain at risk 1
• Some individuals may experience a "honeymoon period" with decreased insulin requirements 1
• Autoantibodies may become undetectable at this stage 1

Critical Care Coordination Points

Across All Stages:

• Foster partnerships between endocrinologists and primary care providers 3
• Provide ongoing psychosocial support tailored to disease stage 3, 6
• Ensure clear communication pathways between specialists and families 6
• Document and track disease progression systematically 2

Primary Care Role: When patients decline specialist care in Stages 1-2, primary care should follow the monitoring guidance outlined above, though specialist care is strongly preferred 2.

The 2025 ADA Standards of Care emphasize that early detection through screening reduces DKA rates at diagnosis and enables access to disease-modifying therapies 1. The shift toward staging-based management represents a fundamental change in type 1 diabetes care, moving from reactive treatment of symptomatic disease to proactive intervention in presymptomatic stages.